Skip to content

Ovid Therapeutics

Ovid Therapeutics is a New York-based biopharmaceutical company developing small molecule medicines for epilepsies and brain conditions.

Last updated September 15, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Ovid Therapeutics is a biopharmaceutical company striving to calm the storm that causes seizures by developing new medicines for neurological and brain conditions. It is a New York-based company dedicated to developing small molecule medicines for brain conditions and symptoms caused by excess neural excitability, and it is advancing a pipeline of novel targeted small molecule candidates. The company states that it was founded with the hope and determination to meaningfully improve the lives of people and families affected by neurological diseases, and that it is developing a next generation of targeted small molecule therapies that seek to reduce seizures and deliver improved safety and tolerability.

History

Ovid Therapeutics states that it was founded with the hope and determination to meaningfully improve the lives of people and families affected by neurological diseases. The company describes itself as a New York-based biopharmaceutical company dedicated to developing small molecule medicines for brain conditions and symptoms caused by excess neural excitability, and as striving to conquer epilepsies and brain conditions with courageous science. It is developing a next generation of targeted small molecule therapies that seek to reduce seizures and deliver improved safety and tolerability, and is advancing a pipeline of novel targeted small molecule candidates. Meg Alexander is described as the former President and Chief Operating Officer of Ovid Therapeutics, and as having helped reshape the company's pipeline and strategic direction since joining Ovid.

Products and positioning

A biopharmaceutical company developing a next generation of targeted small molecule therapies for epilepsies and brain conditions, with compounds having unique or potential best-in-class mechanisms of action.

  • OV329

  • OV4071 & KCC2 Portfolio Program

Sources5 sources

Cite this profile: Cite the canonical profile. /brand-wiki/ovid-therapeutics-united-states · Editorial policy · How profiles are compiled